- ICH GCP
- Реестр клинических исследований США
- Клиническое испытание NCT04586231
Исследование белзутифана (MK-6482) в комбинации с ленватинибом по сравнению с кабозантинибом для лечения почечно-клеточного рака (MK-6482-011)
An Open-label, Randomized, Phase 3 Study of MK-6482 in Combination With Lenvatinib (MK-7902) vs Cabozantinib for Treatment in Participants With Advanced Renal Cell Carcinoma Who Have Progressed After Prior Anti-PD-1/L1 Therapy
This study will compare the efficacy and safety of belzutifan + lenvatinib versus cabozantinib in participants with advanced renal cell carcinoma (RCC) with clear cell component after prior therapy.
The primary hypothesis is that belzutifan + lenvatinib is superior to cabozantinib in terms of progression-free survival or overall survival.
Обзор исследования
Статус
Условия
Вмешательство/лечение
Тип исследования
Регистрация (Действительный)
Фаза
- Фаза 3
Контакты и местонахождение
Места учебы
-
-
New South Wales
-
St Leonards, New South Wales, Австралия, 2065
- GenesisCare North Shore ( Site 4011)
-
-
South Australia
-
Elizabeth Vale, South Australia, Австралия, 5112
- Lyell McEwin Hospital ( Site 4004)
-
-
Victoria
-
Frankston, Victoria, Австралия, 3199
- Peninsula Health Frankston Hospital ( Site 4001)
-
Melbourne, Victoria, Австралия, 3000
- Peter MacCallum Cancer Centre-Parkville Cancer Clinical Trials Unit (PCCTU) ( Site 4010)
-
-
-
-
-
Vienna, Австрия, 1020
- Krankenhaus der Barmherzigen Brüder Wien ( Site 1041)
-
Vienna, Австрия, 1090
- Medizinische Universität Wien ( Site 1021)
-
-
State of Vienna
-
Vienna, State of Vienna, Австрия, 1160
- Klinik Ottakring-1.Medizinische Abteilung - Zentrum für Onkologie und Hämatologie ( Site 1031)
-
-
Styria
-
Graz, Styria, Австрия, 8036
- Medizinische Universitätsklinik Graz ( Site 1051)
-
-
Upper Austria
-
Linz, Upper Austria, Австрия, 4020
- Ordensklinikum Linz GmbH Elisabethinen-Urologie ( Site 1001)
-
-
-
-
Buenos Aires
-
CABA, Buenos Aires, Аргентина, C1120AAT
- Centro de Urología (CDU) ( Site 0803)
-
Ciudad Autónoma de Buenos Aires, Buenos Aires, Аргентина, C1280AEB
- Hospital Británico de Buenos Aires-Oncology ( Site 0801)
-
Ciudad Autónoma de Buenos Aires, Buenos Aires, Аргентина, C1426ANZ
- Instituto Alexander Fleming ( Site 0800)
-
-
Buenos Aires F.D.
-
Buenos Aires, Buenos Aires F.D., Аргентина, C1419AHN
- Asociación de Beneficencia Hospital Sirio Libanés ( Site 0804)
-
-
Santa Fe Province
-
Rosario, Santa Fe Province, Аргентина, 2000
- Sanatorio Británico-Clinical Oncology Department ( Site 0802)
-
Rosario, Santa Fe Province, Аргентина, S2000DSV
- Sanatorio Parque ( Site 0806)
-
-
-
-
-
Liège, Бельгия, 4000
- CHU de Liege ( Site 1102)
-
-
Bruxelles-Capitale, Region de
-
Anderlecht, Bruxelles-Capitale, Region de, Бельгия, 1070
- Institut Jules Bordet ( Site 1103)
-
Brussels, Bruxelles-Capitale, Region de, Бельгия, 1200
- Cliniques Universitaires Saint Luc - Bruxelles ( Site 1105)
-
-
Hainaut
-
Gilly, Hainaut, Бельгия, 6060
- Grand Hopital de Charleroi ( Site 1104)
-
-
Oost-Vlaanderen
-
Ghent, Oost-Vlaanderen, Бельгия, 9000
- UZ Gent ( Site 1100)
-
-
Vlaams-Brabant
-
Leuven, Vlaams-Brabant, Бельгия, 3000
- UZ Leuven ( Site 1101)
-
-
-
-
-
São Paulo, Бразилия, 01321-001
- BP - A Beneficencia Portuguesa de São Paulo-Medical Oncology ( Site 0311)
-
São Paulo, Бразилия, 01321-001
- Hospital Paulistano - Amil Clinical Research ( Site 0308)
-
-
Rio Grande do Norte
-
Natal, Rio Grande do Norte, Бразилия, 59151600
- Liga Norte Riograndense Contra o Cancer ( Site 0313)
-
-
Rio Grande do Sul
-
Porto Alegre, Rio Grande do Sul, Бразилия, 90110-270
- Centro Gaucho Integrado de Oncologia ( Site 0304)
-
-
-
-
-
Berlin, Германия, 10117
- Charite Universitaetsmedizin Berlin ( Site 1321)
-
Berlin, Германия, 13125
- HELIOS Klinikum Berlin-Buch ( Site 1311)
-
-
Baden-Wurttemberg
-
Freiburg im Breisgau, Baden-Wurttemberg, Германия, 79106
- Klinik fuer Urologie ( Site 1303)
-
Heidelberg, Baden-Wurttemberg, Германия, 69120
- NCT-Department of Medical Oncology ( Site 1320)
-
-
Bavaria
-
Nuremberg, Bavaria, Германия, 90419
- Klinikum Nuernberg Nord ( Site 1300)
-
-
Hesse
-
Frankfurt am Main, Hesse, Германия, 60590
- Universitaetsklinikum Frankfurt ( Site 1301)
-
-
North Rhine-Westphalia
-
Aachen, North Rhine-Westphalia, Германия, 52074
- Universitaetsklinikum Aachen AOER ( Site 1317)
-
-
Saarland
-
Homburg/ Saar, Saarland, Германия, 66421
- Universitaetsklinikum des Saarlandes ( Site 1305)
-
-
Saxony-Anhalt
-
Halle, Saxony-Anhalt, Германия, 06120
- Krankenhaus Martha Maria Halle-Doelau ( Site 1314)
-
-
Thuringia
-
Erfurt, Thuringia, Германия, 99089
- Helios Klinikum Erfurt GmbH ( Site 1315)
-
-
-
-
-
Thessaloniki, Греция, 570 01
- European Interbalkan Medical Center-Oncology Department ( Site 3300)
-
-
Achaia
-
Pátrai, Achaia, Греция, 26504
- UNIVERSITY HOSPITAL OF PATRAS-DIVISION OF ONCOLOGY ( Site 3302)
-
-
Attica
-
Athens, Attica, Греция, 115 28
- Alexandra General Hospital of Athens-ONCOLOGY DEPT. ( Site 3304)
-
Athens, Attica, Греция, 151 25
- Athens Medical Center ( Site 3303)
-
Chaïdári, Attica, Греция, 124 62
- ATTIKON GENERAL UNIVERSITY HOSPITAL ( Site 3301)
-
-
-
-
-
Dublin, Ирландия, D24NR0A
- Tallaght University Hospital ( Site 3200)
-
Dublin, Ирландия, D07 R2WY
- Mater Misericordiae University Hospital ( Site 3201)
-
Dublin, Ирландия, D07 R2WY
- Mater Private Hospital - Dublin ( Site 3202)
-
-
-
-
-
Barcelona, Испания, 08035
- Hospital Universitari Vall d'Hebron-Departamento de Oncologia- VHIO ( Site 1507)
-
Barcelona, Испания, 08036
- Hospital Clinic i Provincial ( Site 1500)
-
Barcelona, Испания, 08041
- Hospital Santa Creu i Sant Pau ( Site 1501)
-
Madrid, Испания, 28009
- Hospital General Universitario Gregorio Maranon ( Site 1505)
-
Madrid, Испания, 28040
- Hospital Clinico San Carlos... ( Site 1504)
-
Seville, Испания, 41013
- Hospital Virgen del Rocio ( Site 1503)
-
-
La Coruna
-
A Coruña, La Coruna, Испания, 15006
- Complejo Hospitalario Universitario A Coruna ( Site 1502)
-
-
Madrid, Comunidad de
-
Madrid, Madrid, Comunidad de, Испания, 28041
- Hospital Universitario 12 de Octubre-Medical Oncology ( Site 1508)
-
-
-
-
-
Arezzo, Италия, 52100
- Medical Oncology Ospedale San Donato ( Site 1404)
-
Bari, Италия, 70124
- Azienda Ospedaliera Policlinico di Bari ( Site 1402)
-
Milan, Италия, 20132
- IRCCS Ospedale San Raffaele ( Site 1409)
-
Milan, Италия, 20133
- Fondazione IRCCS Istituto Nazionale dei Tumori di Milano ( Site 1400)
-
Pavia, Италия, 27100
- Istituti Clinici Scientifici Maugeri Spa ( Site 1403)
-
Roma, Италия, 00168
- Fondazione Policlinico Universitario Agostino Gemelli-Medical Oncology ( Site 1410)
-
Terni, Италия, 05100
- Azienda Ospedaliera S. Maria di Terni ( Site 1401)
-
Verona, Италия, 37126
- Ospedale Maggiore Borgo Trento ( Site 1408)
-
-
Forli-Cesena
-
Meldola, Forli-Cesena, Италия, 47014
- Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori ( Site 1407)
-
-
Milano
-
Rozzano, Milano, Италия, 20089
- Istituto Clinico Humanitas Research Hospital ( Site 1406)
-
-
Torino
-
Orbassano, Torino, Италия, 10043
- Ospedale San Luigi Gonzaga ( Site 1405)
-
-
-
-
Alberta
-
Calgary, Alberta, Канада, T2N 5G2
- Arthur J.E. Child Comprehensive Cancer Centre ( Site 0109)
-
Edmonton, Alberta, Канада, T6G 1Z2
- Cross Cancer Institute ( Site 0111)
-
-
British Columbia
-
Vancouver, British Columbia, Канада, V5Z 4E6
- BC Cancer Vancouver-Clinical Trials Unit ( Site 0110)
-
-
New Brunswick
-
Moncton, New Brunswick, Канада, E1C 6Z8
- The Moncton Hospital ( Site 0101)
-
-
Ontario
-
Hamilton, Ontario, Канада, L8V 5C2
- Hamilton Health Sciences-Juravinski Cancer Centre ( Site 0114)
-
Kingston, Ontario, Канада, K7L 2V7
- Kingston Health Sciences Centre ( Site 0105)
-
Ottawa, Ontario, Канада, K1H 8L6
- The Ottawa Hospital - General Campus-The Ottawa Hospital Cancer Centre ( Site 0116)
-
Toronto, Ontario, Канада, M4N 3M5
- Sunnybrook Health Sciences - Odette Cancer Centre ( Site 0113)
-
-
Quebec
-
Greenfield Park, Quebec, Канада, J4V 2H1
- CISSS de la Monteregie-Centre ( Site 0103)
-
Québec, Quebec, Канада, G1J 1Z4
- Centre intégré de cancérologie du CHU de Québec Université Laval, Hôpital de l'Enfant-Jésus ( Site 0115)
-
Sherbrooke, Quebec, Канада, J1H 5N4
- CIUSSS de l Estrie - CHUS - Centre Hosp. Univ. Sherbrooke ( Site 0102)
-
-
-
-
Antioquia
-
Medellín, Antioquia, Колумбия, 050030
- Fundacion Colombiana de Cancerología Clinica Vida ( Site 0505)
-
-
Cesar Department
-
Valledupar, Cesar Department, Колумбия, 200001
- Sociedad De Oncologia Y Hematologia Del Cesar-Oncology ( Site 0508)
-
-
Cundinamarca
-
Bogotá, Cundinamarca, Колумбия, 111511
- Instituto Nacional de Cancerología-Clinical Oncology ( Site 0500)
-
-
Santander Department
-
Piedecuesta, Santander Department, Колумбия, 681017
- Fundación Cardiovascular de Colombia ( Site 0501)
-
-
-
-
-
Utrecht, Нидерланды, 3584 CX
- Universitair Medisch Centrum Utrecht ( Site 1910)
-
-
Limburg
-
Sittard-Geleen, Limburg, Нидерланды, 6162 BG
- Zuyderland Medical Centre-Trialbureau Interne Geneeskunde ( Site 1904)
-
-
North Brabant
-
Breda, North Brabant, Нидерланды, 4818 CK
- Amphia Hospital Location Molengracht ( Site 1912)
-
-
North Holland
-
Amsterdam, North Holland, Нидерланды, 1066 CX
- Antoni van Leeuwenhoek Ziekenhuis ( Site 1901)
-
-
Provincie Friesland
-
Leeuwarden, Provincie Friesland, Нидерланды, 8934 AD
- Medisch Centrum Leeuwarden ( Site 1905)
-
-
South Holland
-
Rotterdam, South Holland, Нидерланды, 3015 GD
- Erasmus MC ( Site 1913)
-
Schiedam, South Holland, Нидерланды, 3118 JH
- Franciscus Gasthuis & Vlietland, Locatie Vlietland ( Site 1909)
-
The Hague, South Holland, Нидерланды, 2545 AA
- Haga Ziekenhuis locatie Leyweg-Oncology ( Site 1917)
-
-
-
-
Greater Poland Voivodeship
-
Poznan, Greater Poland Voivodeship, Польша, 60-569
- Uniwersytecki Szpital Kliniczny w Poznaniu ( Site 2401)
-
-
Kuyavian-Pomeranian Voivodeship
-
Bydgoszcz, Kuyavian-Pomeranian Voivodeship, Польша, 85-796
- Centrum Onkologii im. Prof. Franciszka Lukaszczyka ( Site 2402)
-
-
Lesser Poland Voivodeship
-
Krakow, Lesser Poland Voivodeship, Польша, 31-115
- Narodowy Instytut Onkologii im. Marii Sklodowskiej-Curie - O-Klinika Onkologii Klinicznej ( Site 2403)
-
-
Masovian Voivodeship
-
Warsaw, Masovian Voivodeship, Польша, 02-781
- Narodowy Instytut Onkologii im. Marii Sklodowskiej-Curie ( Site 2400)
-
-
-
-
Ivanovo Oblast
-
Ivanovo, Ivanovo Oblast, Россия, 153040
- Ivanovo Regional Oncology Dispensary ( Site 2616)
-
-
Moscow
-
Moscow, Moscow, Россия, 119285
- FSBI United Hospital with Polyclinic ( Site 2613)
-
Moscow, Moscow, Россия, 125130
- SHI of Moscow City Oncology Clinical Hospital - 62 ( Site 2614)
-
-
Moscow Oblast
-
Krasnogorsk, Moscow Oblast, Россия, 143442
- MEDSI Clinical Hospital on Pyatnitsky Highway-Departmentof Antitumor Drug therapy ( Site 2618)
-
Moscow, Moscow Oblast, Россия, 121205
- Hadassah Medical-Oncology department ( Site 2609)
-
-
Volgograd Oblast
-
Volzhsky, Volgograd Oblast, Россия, 404120
- Volgograd Regional Uronephrological Center ( Site 2615)
-
-
Yaroslavl Oblast
-
Yaroslavl, Yaroslavl Oblast, Россия, 150054
- Yaroslavl Regional Cancer Hospital-Oncology ( Site 2619)
-
-
-
-
Cluj
-
Cluj-Napoca, Cluj, Румыния, 400015
- Institutul Oncologic Prof.Dr. Ion Chiricuta Cluj-Napoca ( Site 2500)
-
Cluj-Napoca, Cluj, Румыния, 400015
- Institutul Oncologic Prof.Dr. Ion Chiricuta Cluj-Napoca ( Site 2501)
-
-
Dolj
-
Craiova, Dolj, Румыния, 200542
- Centrul de Oncologie "Sfântul Nectarie" ( Site 2502)
-
-
-
-
Aberdeen City
-
Aberdeen, Aberdeen City, Соединенное Королевство, AB25 2ZN
- Aberdeen Royal Infirmary-Department of Oncology ( Site 3105)
-
-
Bath And North East Somerset
-
Bath, Bath And North East Somerset, Соединенное Королевство, BA1 3NG
- Royal United Hospital Bath England ( Site 3108)
-
-
England
-
Nottingham, England, Соединенное Королевство, NG5 1PF
- Nottingham University Hospitals NHS Trust. City Hospital Campus ( Site 3106)
-
-
Essex
-
Southend, Essex, Соединенное Королевство, SS0 0RY
- Southend University Hospital ( Site 3112)
-
-
London, City of
-
London, London, City of, Соединенное Королевство, W6 8RF
- Imperial Healthcare NHS Trust Charing Cross Hospital ( Site 3107)
-
Northwood, London, City of, Соединенное Королевство, HA6 2RN
- Mount Vernon Cancer Centre ( Site 3101)
-
-
Somerset
-
Taunton, Somerset, Соединенное Королевство, TA1 5DA
- Musgrove Park Hospital ( Site 3103)
-
-
Wales
-
Swansea, Wales, Соединенное Королевство, SA2 8QA
- Singleton Hospital ( Site 3111)
-
-
-
-
Arizona
-
Chandler, Arizona, Соединенные Штаты, 85224
- Ironwood Cancer & Research Centers ( Site 0077)
-
-
California
-
Los Angeles, California, Соединенные Штаты, 90048
- Cedars Sinai Medical Center ( Site 0027)
-
Los Angeles, California, Соединенные Штаты, 90404
- UCLA Hematology/Oncology - Santa Monica ( Site 0048)
-
Orange, California, Соединенные Штаты, 92868
- St. Joseph Hospital-The Center for Cancer Prevention and Treatment ( Site 0095)
-
Orange, California, Соединенные Штаты, 92868
- University of California, Irvine ( Site 0029)
-
Santa Monica, California, Соединенные Штаты, 90404
- Providence Saint John's Health Center ( Site 0083)
-
-
District of Columbia
-
Washington D.C., District of Columbia, Соединенные Штаты, 20007
- Georgetown University Medical Center ( Site 0006)
-
-
Florida
-
Orlando, Florida, Соединенные Штаты, 32806
- Orlando Health, Inc. ( Site 0035)
-
Orlando, Florida, Соединенные Штаты, 32804
- AdventHealth Orlando-AdventHealth Medical Group Hematology & Oncology at Orlandoc ( Site 0003)
-
-
Georgia
-
Athens, Georgia, Соединенные Штаты, 30607
- University Cancer & Blood Center, LLC ( Site 0057)
-
Atlanta, Georgia, Соединенные Штаты, 30322
- Emory University Hospital ( Site 0012)
-
-
Illinois
-
Chicago, Illinois, Соединенные Штаты, 60607
- Rush University Medical Center ( Site 0040)
-
Peoria, Illinois, Соединенные Штаты, 61615
- Illinois Cancer Care, PC ( Site 0008)
-
-
Indiana
-
Fort Wayne, Indiana, Соединенные Штаты, 46845
- Parkview Cancer Institute ( Site 0088)
-
-
Kentucky
-
Louisville, Kentucky, Соединенные Штаты, 40207
- Norton Cancer Institute - St. Matthews ( Site 0065)
-
-
Louisiana
-
New Orleans, Louisiana, Соединенные Штаты, 70112
- Tulane University School of Medicine ( Site 0098)
-
-
Massachusetts
-
Burlington, Massachusetts, Соединенные Штаты, 01805
- Lahey Hospital & Medical Center ( Site 0090)
-
-
Michigan
-
Grand Rapids, Michigan, Соединенные Штаты, 49503
- Cancer & Hematology Centers of Western Michigan ( Site 0018)
-
-
Minnesota
-
Saint Louis Park, Minnesota, Соединенные Штаты, 55426
- HealthPartners Cancer Research Center-HealthPartners Frauenshuh Cancer Center ( Site 0005)
-
-
Mississippi
-
Jackson, Mississippi, Соединенные Штаты, 39213
- University of Mississippi Medical Ctr ( Site 0037)
-
-
Nebraska
-
Lincoln, Nebraska, Соединенные Штаты, 68516
- Cancer Partners of Nebraska ( Site 0086)
-
-
New Jersey
-
New Brunswick, New Jersey, Соединенные Штаты, 08903
- Rutgers Cancer Institute of New Jersey ( Site 0078)
-
-
New York
-
Lake Success, New York, Соединенные Штаты, 11042
- R.J. Zuckerberg Cancer Center-Medical Oncology ( Site 0013)
-
New York, New York, Соединенные Штаты, 10065
- Memorial Sloan Kettering Cancer Center ( Site 0055)
-
-
North Carolina
-
Charlotte, North Carolina, Соединенные Штаты, 28204
- Levine Cancer Institute ( Site 0004)
-
Durham, North Carolina, Соединенные Штаты, 27710
- Duke Cancer Institute ( Site 0096)
-
-
Pennsylvania
-
Allentown, Pennsylvania, Соединенные Штаты, 18103
- Lehigh Valley Hospital- Cedar Crest-Oncology Clinical Trials ( Site 0056)
-
-
Texas
-
Dallas, Texas, Соединенные Штаты, 75235
- University of Texas, Southwestern Medical Center ( Site 0015)
-
-
Utah
-
Salt Lake City, Utah, Соединенные Штаты, 84112
- Huntsman Cancer Institute-HCI Clinical Trials Office ( Site 7001)
-
-
Vermont
-
Burlington, Vermont, Соединенные Штаты, 05401
- University of Vermont Medical Center ( Site 0001)
-
-
Virginia
-
Roanoke, Virginia, Соединенные Штаты, 24014
- Blue Ridge Cancer Care - Roanoke ( Site 0043)
-
-
Washington
-
Seattle, Washington, Соединенные Штаты, 98109
- Seattle Cancer Care Alliance-Renal/Melanoma/MCC ( Site 0093)
-
Wenatchee, Washington, Соединенные Штаты, 98801
- Central Washington Health Services Association d/b/a Confluence Health ( Site 0061)
-
-
-
-
Pirkanmaa
-
Tampere, Pirkanmaa, Финляндия, 33520
- Tampereen yliopistollinen sairaala ( Site 1801)
-
-
Southwest Finland
-
Turku, Southwest Finland, Финляндия, 20520
- TYKS ( Site 1802)
-
-
Uusimaa
-
Helsinki, Uusimaa, Финляндия, 00290
- HYKS ( Site 1800)
-
-
-
-
-
Paris, Франция, 75020
- Hopital Tenon ( Site 1213)
-
-
Ain
-
Reims, Ain, Франция, 51726
- Institut Jean Godinot ( Site 1216)
-
-
Alpes-Maritimes
-
Nice, Alpes-Maritimes, Франция, 06189
- Centre Antoine Lacassagne ( Site 1217)
-
-
Bas-Rhin
-
Strasbourg, Bas-Rhin, Франция, 67200
- Hopitaux Universitaires de Strasbourg- Hopital de Hautepierre ( Site 1218)
-
-
Gironde
-
Bordeaux, Gironde, Франция, 33000
- CHU de Bordeaux- Hopital Saint Andre ( Site 1209)
-
-
Haute-Garonne
-
Toulouse, Haute-Garonne, Франция, 31059
- Institut Claudius Regaud ( Site 1215)
-
-
Haute-Vienne
-
Limoges, Haute-Vienne, Франция, 87039
- Clinique Francois Chenieux ( Site 1210)
-
-
Loire-Atlantique
-
Saint-Herblain, Loire-Atlantique, Франция, 44805
- Institut de Cancerologie de l Ouest Centre Rene Gauducheau ( Site 1201)
-
-
Maine-et-Loire
-
Angers, Maine-et-Loire, Франция, 49055
- Institut de Cancerologie de l Ouest Site Paul Papin ( Site 1200)
-
-
-
-
-
Hradec Králové, Чехия, 500 05
- Fakultni nemocnice Hradec Kralove-Klinika onkologie a radioterapie ( Site 2201)
-
-
Brno-mesto
-
Brno, Brno-mesto, Чехия, 656 53
- Masarykuv onkologicky ustav-Klinika komplexni onkologicke pece ( Site 2203)
-
-
Praha 4
-
Prague, Praha 4, Чехия, 140 59
- Fakultni Thomayerova nemocnice-Onkologicka klinika 1. LF UK ( Site 2200)
-
-
Praha 5
-
Prague, Praha 5, Чехия, 150 06
- Fakultni nemocnice v Motole-Onkologicka klinika 2. LF UK a FN Motol ( Site 2205)
-
-
South Bohemian Region
-
České Budějovice, South Bohemian Region, Чехия, 37001
- Nemocnice Ceske Budejovice-Onkologicke oddeleni ( Site 2204)
-
-
-
-
Araucania
-
Temuco, Araucania, Чили, 4800827
- James Lind Centro de Investigacion del Cancer ( Site 0402)
-
-
Region M. de Santiago
-
Santiago, Region M. de Santiago, Чили, 8420383
- Bradfordhill-Clinical Area ( Site 0400)
-
-
-
-
Canton Ticino
-
Bellinzona, Canton Ticino, Швейцария, 6500
- Istituto Oncologica della Svizzera Italiana (IOSI) ( Site 1604)
-
-
Canton of Geneva
-
Geneva, Canton of Geneva, Швейцария, 1211
- Hopitaux Universitaires de Geneve HUG ( Site 1602)
-
-
Canton of Zurich
-
Zurich, Canton of Zurich, Швейцария, 8001
- Universitaetsspital Zuerich ( Site 1601)
-
-
Kanton Graubünden
-
Chur, Kanton Graubünden, Швейцария, 7000
- Kantonsspital Graubuenden ( Site 1600)
-
-
-
-
-
Seoul, Южная Корея, 05505
- Asan Medical Center ( Site 4200)
-
Seoul, Южная Корея, 06351
- Samsung Medical Center ( Site 4201)
-
-
Jeonranamdo
-
Hwasun, Jeonranamdo, Южная Корея, 58128
- Chonnam National University Hwasun Hospital-Oncology ( Site 4203)
-
-
-
-
-
Fukuoka, Япония, 812-8582
- Kyushu University Hospital ( Site 5005)
-
Niigata, Япония, 951-8520
- Niigata University Medical & Dental Hospital ( Site 5013)
-
Osaka, Япония, 541-8567
- Osaka Prefectural Hospital Organization Osaka International Cancer Institute ( Site 5016)
-
Tokyo, Япония, 113-8603
- Nippon Medical School Hospital ( Site 5006)
-
Tokyo, Япония, 123-8558
- Tokyo Women's Medical University Adachi Medical Center ( Site 5015)
-
Tokyo, Япония, 160-8582
- Keio University Hospital ( Site 5011)
-
-
Aichi-ken
-
Toyoake, Aichi-ken, Япония, 470-1192
- Fujita Health University Hospital ( Site 5003)
-
-
Chiba
-
Kashiwa, Chiba, Япония, 2778577
- National Cancer Center Hospital East ( Site 5000)
-
Sakura, Chiba, Япония, 285-8741
- Toho University Sakura Medical Center ( Site 5014)
-
-
Hokkaido
-
Sapporo, Hokkaido, Япония, 060-8543
- Sapporo Medical University Hospital ( Site 5008)
-
-
Hyōgo
-
Kobe, Hyōgo, Япония, 650-0047
- Kobe City Medical Center General Hospital ( Site 5017)
-
-
Kanagawa
-
Yokohama, Kanagawa, Япония, 236-0004
- Yokohama City University Hospital ( Site 5007)
-
-
Nara
-
Kashihara, Nara, Япония, 634-0813
- Nara Medical University Hospital ( Site 5002)
-
-
Osaka
-
Sakai, Osaka, Япония, 590-0197
- Kindai University Hospital ( Site 5010)
-
Suita, Osaka, Япония, 565-0871
- The University of Osaka Hospital ( Site 5012)
-
-
Shizuoka
-
Hamamatsu, Shizuoka, Япония, 431-3192
- Hamamatsu University Hospital ( Site 5004)
-
-
Tokyo
-
Bunkyo-ku, Tokyo, Япония, 113-8510
- Institute of Science Tokyo Hospital ( Site 5009)
-
Minato-ku, Tokyo, Япония, 105-8470
- Toranomon Hospital ( Site 5001)
-
-
Критерии участия
Критерии приемлемости
Возраст, подходящий для обучения
Принимает здоровых добровольцев
Полы, имеющие право на обучение
Описание
Inclusion Criteria:
- Unresectable, locally advanced or metastatic clear cell renal cell carcinoma (RCC)
- Disease progression on or after an anti-programmed cell death-1/ligand 1 (PD-1/L1) therapy as either first or second-line treatment for locally advanced/metastatic RCC or as adjuvant treatment or neoadjuvant/adjuvant with progression on or within 6 months of last dose
- Measurable disease per Response Evaluation Criteria in Solid Tumors (RECIST 1.1) criteria as assessed by local study investigator
- Karnofsky performance status (KPS) score of at least 70% assessed within 10 days before randomization
- Received no more than 2 prior systemic regimens including: one anti-PD-1/L1 containing adjuvant or neoadjuvant/adjuvant regimens with progression on or within 6 months from the last dose of that regimen OR one or 2 regimens for locoregional/advanced disease
- Received only 1 prior antiPD-1/L1 therapy for adjuvant, neoadjuvant/adjuvant or locally advanced/metastatic RCC
- A male participant is eligible to participate if he is abstinent from heterosexual intercourse or agrees to use contraception during the intervention period and for at least 7 days after the last dose of belzutifan or lenvatinib in the belzutifan+lenvatinib arm, whichever occurs last, and 23 days after the last dose of cabozantinib
- A female participant is eligible to participate if they are not pregnant, not breastfeeding, and at least 1 of the following conditions applies: Not a woman of childbearing potential (WOCBP) or a WOCBP who agrees to follow the contraceptive guidance during the intervention period and for at least 30 days after the last dose of study intervention in the belzutifan+ lenvatinib arm, or 120 days after the last dose of study intervention in the cabozantinib arm
- Adequately controlled blood pressure
- Adequate organ function
Exclusion Criteria:
- A pulse oximeter reading <92% at rest, requires intermittent supplemental oxygen, or requires chronic supplemental oxygen
- Known additional malignancy that is progressing or has required active treatment within the past 3 years except for basal cell carcinoma of the skin, squamous cell carcinoma of the skin, or carcinoma in situ (eg, breast carcinoma, cervical cancer in situ) that have undergone potentially curative therapy
- Known central nervous system (CNS) metastases and/or carcinomatous meningitis
- Clinically significant cardiac disease within 6 months of first dose of study intervention
- Prolongation of corrected QT interval (QTc) interval to >480 ms.
- Symptomatic pleural effusion (e.g.,cough, dyspnea, pleuritic chest pain) that is not clinically stable
- Pre-existing ≥Grade 3 gastrointestinal or nongastrointestinal fistula.
- Moderate to severe hepatic impairment
- History of significant bleeding within 3 months before randomization.
- History of solid organ transplantation
- Known psychiatric or substance abuse disorder that would interfere with cooperation with the requirements of the study
- Unable to swallow orally administered medication or has a gastrointestinal disorder affecting absorption (e.g., gastrectomy, partial bowel obstruction, malabsorption)
- Known hypersensitivity or allergy to the active pharmaceutical ingredients or any component of the study intervention formulations
- Received colony-stimulating factors [eg, granulocyte colony-stimulating factor (G-CSF), granulocyte macrophage colony-stimulating factor (GMCSF) or recombinant erythropoietin (EPO)] within 28 days before randomization
- Prior treatment with belzutifan or another hypoxia-inducible factor (HIF)-2α inhibitor
- Prior treatment with lenvatinib
- Prior treatment with cabozantinib
- Currently participating in a study of an investigational agent or using an investigational device
- Active infection requiring systemic therapy
- History of human immunodeficiency virus (HIV) infection
- History of hepatitis B or known active hepatitis C infection
Учебный план
Как устроено исследование?
Детали дизайна
- Основная цель: Уход
- Распределение: Рандомизированный
- Интервенционная модель: Параллельное назначение
- Маскировка: Нет (открытая этикетка)
Оружие и интервенции
Группа участников / Армия |
Вмешательство/лечение |
|---|---|
|
Экспериментальный: Belzutifan + Lenvatinib
Participants received daily oral dose of belzutifan 120 mg and lenvatinib 20 mg until progressive disease or discontinuation. |
Oral administration
Другие имена:
Oral administration
Другие имена:
|
|
Активный компаратор: Cabozantinib
Participants received daily oral dose of cabozantinib 60 mg until progressive disease or discontinuation. |
Oral administration
Другие имена:
|
Что измеряет исследование?
Первичные показатели результатов
Мера результата |
Мера Описание |
Временное ограничение |
|---|---|---|
|
Progression-Free Survival (PFS) per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) as Assessed by Blinded Independent Central Review (BICR)
Временное ограничение: Up to approximately 34 months
|
PFS is defined as the time from randomization to the first documented progressive disease (PD) or death due to any cause, whichever occurs first. Per RECIST 1.1, PD is defined as ≥20% increase in the sum of diameters of target lesions. In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of ≥5 mm. The appearance of one or more new lesions is also considered PD. PFS as assessed by blinded independent central review will be presented. |
Up to approximately 34 months
|
|
Overall Survival (OS)
Временное ограничение: Up to approximately 44 months
|
OS is defined as time from randomization to death due to any cause. |
Up to approximately 44 months
|
Вторичные показатели результатов
Мера результата |
Мера Описание |
Временное ограничение |
|---|---|---|
|
Objective Response Rate (ORR) per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) as Assessed by Blinded Independent Central Review (BICR)
Временное ограничение: Up to approximately 24 months
|
ORR is defined as the percentage of participants who have a complete response (CR: Disappearance of all target lesions) or a partial response (PR: At least a 30% decrease in the sum of diameters of target lesions) per RECIST 1.1. The percentage of participants who experience a CR or PR as assessed by blinded independent central review based on RECIST 1.1 will be presented. |
Up to approximately 24 months
|
|
Duration of Response (DOR) per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) as Assessed by Blinded Independent Central Review (BICR)
Временное ограничение: Up to approximately 44 months
|
For participants who demonstrate a confirmed complete response (CR: Disappearance of all target lesions) or confirmed partial response (PR: At least a 30% decrease in the sum of diameters of target lesions) per RECIST 1.1, DOR is defined as the time from first documented evidence of CR or PR until disease progression or death. The DOR as assessed by blinded independent central review will be presented. |
Up to approximately 44 months
|
|
Number of Participants Who Experienced One or More Adverse Events (AEs)
Временное ограничение: Up to approximately 44 months
|
An adverse event (AE) is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of a study intervention. |
Up to approximately 44 months
|
|
Number of Participants Who Discontinued Study Treatment Due to an Adverse Event (AE)
Временное ограничение: Up to approximately 44 months
|
An adverse event (AE) is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of a study intervention. |
Up to approximately 44 months
|
Соавторы и исследователи
Спонсор
Соавторы
Следователи
- Директор по исследованиям: Medical Director, Merck Sharp & Dohme LLC
Публикации и полезные ссылки
Общие публикации
- Motzer RJ, Schmidinger M, Eto M, Suarez C, Figlin R, Liu Y, Perini R, Zhang Y, Heng DY. LITESPARK-011: belzutifan plus lenvatinib vs cabozantinib in advanced renal cell carcinoma after anti-PD-1/PD-L1 therapy. Future Oncol. 2023 Jan;19(2):113-121. doi: 10.2217/fon-2022-0802. Epub 2023 Feb 8.
- Motzer RJ, McDermott R, Park SH, Burotto M, Iacovelli R, Verzoni E, Suarez C, Eto M, Cutuli HJ, Porta C, Kopp RM, Rottey S, Velasco G, Valderrama BP, Azad AA, Giorgi U, Pavic M, Tomczak P, Figlin R, Westgeest HM, Guida A, Necchi A, Schutz FA, Suelmann BBM, Haanen JBAG, Yuan SS, Perini RF, Wang D, Heng DYC, Schmidinger M; LITESPARK-011 Investigators. Belzutifan plus lenvatinib versus cabozantinib in patients with previously treated advanced renal cell carcinoma (LITESPARK-011): an open-label, randomised, controlled, phase 3 trial. Lancet. 2026 Aug 12:S0140-6736(26)01089-5. doi: 10.1016/S0140-6736(26)01089-5. Online ahead of print.
- Heng DYC, Schmidinger M, McDermott R, Park SH, Burotto M, Ciccarese C, Verzoni E, Suarez C, Eto M, Cutuli HJ, Porta C, Kopp RM, Rottey S, de Velasco G, Valderrama BP, Azad AA, De Giorgi U, Pavic M, Tomczak P, Figlin R, Westgeest HM, Guida A, Necchi A, Schutz FA, Suelmann BBM, Haanen JB, Lin J, Perini RF, Vickery D, Motzer RJ; LITESPARK-011 Investigators. Final prespecified analysis of the phase 3 LITESPARK-011 study: belzutifan plus lenvatinib versus cabozantinib for advanced renal cell carcinoma after anti-PD-(L)1 therapy. Ann Oncol. 2026 Oct 25:S0923-7534(26)06893-6. doi: 10.1016/j.annonc.2026.10.109. Online ahead of print.
Полезные ссылки
Даты записи исследования
Изучение основных дат
Начало исследования (Действительный)
Первичное завершение (Действительный)
Завершение исследования (Оцененный)
Даты регистрации исследования
Первый отправленный
Впервые представлено, что соответствует критериям контроля качества
Первый опубликованный (Действительный)
Обновления учебных записей
Последнее опубликованное обновление (Действительный)
Последнее отправленное обновление, отвечающее критериям контроля качества
Последняя проверка
Дополнительная информация
Термины, связанные с этим исследованием
Дополнительные соответствующие термины MeSH
- Урогенитальные заболевания
- Урогенитальные новообразования
- Новообразования по локализации
- Новообразования
- Мужские мочеполовые заболевания
- Заболевания почек
- Урологические заболевания
- Женские урогенитальные заболевания
- Женские мочеполовые заболевания и осложнения беременности
- Новообразования по гистологическому типу
- Новообразования железистые и эпителиальные
- Аденокарцинома
- Урологические новообразования
- Карцинома
- Новообразования почек
- Карцинома, почечно-клеточная
- кабозантиниб
- Белзутифан
- Lenvatinib
Другие идентификационные номера исследования
- 6482-011
- MK-6482-011 (Другой идентификатор: MSD)
- jRCT2031210311 (Другой идентификатор: jRCT(Japan Registry of Clinical Trials))
- 2020-002075-35 (Номер EudraCT)
- U1111-1302-2815 (Идентификатор реестра: UTN)
- 2024-510620-39-00 (Идентификатор реестра: EU CT)
Планирование данных отдельных участников (IPD)
Планируете делиться данными об отдельных участниках (IPD)?
Описание плана IPD
https://trialstransparency.msdclinicaltrials.com/pdf/ProcedureAccessClinicalTrialData.pdf
Информация о лекарствах и устройствах, исследовательские документы
Изучает лекарственный продукт, регулируемый FDA США.
Изучает продукт устройства, регулируемый Управлением по санитарному надзору за качеством пищевых продуктов и медикаментов США.
Эта информация была получена непосредственно с веб-сайта clinicaltrials.gov без каких-либо изменений. Если у вас есть запросы на изменение, удаление или обновление сведений об исследовании, обращайтесь по адресу register@clinicaltrials.gov. Как только изменение будет реализовано на clinicaltrials.gov, оно будет автоматически обновлено и на нашем веб-сайте. .